Literature DB >> 25755611

Surveillance for hepatocellular carcinoma.

Jeyamani Ramachandran1.   

Abstract

Hepatocellular carcinoma (HCC) is a dreaded complication of cirrhosis as it is the commonest cause of mortality in these patients. The last few years have seen a dramatic improvement in the management of this tumor as nearly 50-70% of selected patients with early HCC survive for a median period of up to 5 years after liver transplantation, resection or local ablation. Surveillance has been found to be an effective tool to detect early tumors and expand the applicability of these curative treatment options. Semiannual ultrasonogram is recommended for surveillance by the American, European and Asia Pacific liver societies and is the standard of care in many countries. There is increasing evidence that this practice improves survival too. Since the only way to improve the outlook of HCC is its diagnosis prior to commencement of symptoms, providing surveillance becomes a major responsibility of physicians caring for patients with chronic liver disease. This review attempts to discuss the population at risk of HCC, modalities and frequency of surveillance tests, cost effectiveness and also the logistics of its delivery in the Indian context.

Entities:  

Keywords:  HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; NAFLD, non-alcoholic fatty liver disease; RCTs, randomized controlled trials; USG, ultrasonogram; cirrhosis; hepatocellular carcinoma; surveillance

Year:  2014        PMID: 25755611      PMCID: PMC4284216          DOI: 10.1016/j.jceh.2014.03.050

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  70 in total

1.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Authors:  Adrian M Di Bisceglie; Richard K Sterling; Raymond T Chung; James E Everhart; Jules L Dienstag; Herbert L Bonkovsky; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; William M Lee; Timothy R Morgan; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

3.  Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.

Authors:  Hashem B El-Serag; Jennifer R Kramer; G John Chen; Zhigang Duan; Peter A Richardson; Jessica A Davila
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

4.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

5.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

Review 6.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

7.  Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

Authors:  Mauro Manno; Calogero Cammà; Filippo Schepis; Fabio Bassi; Roberta Gelmini; Francesco Giannini; Francesca Miselli; Antonella Grottola; Ilva Ferretti; Chiara Vecchi; Marisa De Palma; Erica Villa
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

8.  Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival.

Authors:  Franco Trevisani; Maria C Cantarini; Antonello M M Labate; Stefania De Notariis; Gianludovico Rapaccini; Fabio Farinati; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi
Journal:  Am J Gastroenterol       Date:  2004-08       Impact factor: 10.864

9.  Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

Authors:  J J Y Sung; K K F Tsoi; V W S Wong; K C T Li; H L Y Chan
Journal:  Aliment Pharmacol Ther       Date:  2008-07-24       Impact factor: 8.171

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  3 in total

1.  Hepatobiliary quiz-12 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12

Review 2.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Silencing the Girdin gene enhances radio-sensitivity of hepatocellular carcinoma via suppression of glycolytic metabolism.

Authors:  Li Yu; Yifan Sun; Jingjing Li; Yan Wang; Yuxing Zhu; Yong Shi; Xiaojun Fan; Jianda Zhou; Ying Bao; Jie Xiao; Ke Cao; Peiguo Cao
Journal:  J Exp Clin Cancer Res       Date:  2017-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.